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Abstract 
Performance Leakage for Biospan-Covered Electrospun 
Vascular Stents in a Pulsatile Flow Bioreactor 
Patrick R. Thompson 
Peter I. Lelkes, Ph.D. 
 
In-stent restenosis occurs in 15-20% of “simple” coronary lesions, and in 30-60% of 
patients with complex lesions.  Covered-stents reduce the rates of in-stent restenosis by 
providing a membrane barrier which prevents late tissue ingrowth.  In developing 
covered-stents it is vital to ensure that these novel stents are capable of enduring 
physiological conditions before implantation.  This thesis focuses on quantifying the 
performance of polyurethane covered stents when placed under a variety of physiological 
and pathological conditions. 
Commercially available Ephesos coronary stents (4 mm diameter following inflation) 
were covered by electrospinning polyurethane onto a bare-metal stainless steel stents for 
6, 8, and 10 minutes.  The inflated polyurethane covered-stents were placed into a 
custom-modified Tissue Growth Technologies LumeGen bioreactor, which allows for 
independent control of key parameters of fluid flow, such as continuous vs. pulsatile f 
low, flow rate and pressure. The polyurethane covered-stents were exposed to various 
physiological and pathological conditions in a controlled setting focusing on flow rate, 
pressure, pulsatility, and amplitude of oscillation allowed as design criteria.  The readout 
for the performance of these polyurethane stents was the fluid leakage as a function these 
various parameters. 
Our data showed no difference in leakage in terms of the duration of the electrospun 
coating, the fluid flow rate or the amplitude of the oscillations of the pulsatile flow.  The 
leakage increased with increasing pressure, while increased fluid viscosity resulted in 
reduced leakage. These preliminary results indicate that electrospun polyurethane 
covered-stent can withstand significant physiological and pathophysiological fluid flow 
conditions. Such covered stents may find applications in reducing restenosis.   
Chapter 1: Introduction 
Cardiovascular disease, also known as heart disease, is the leading cause of death in the 
United States from 2000 to 2010.  In 2010 alone, 24.2% of the total deaths were due to 
cardiovascular disease (Murphy, Xu et al. 2013).  According to the American Heart 
Association, there is no way to accurately quantify and track the full magnitude 
cardiovascular disease has, but estimates state that in 2009 it cost the nation $312.6 
billion in direct costs and lost productivity.  The number of cardiovascular operations and 
procedures increased 28% from 2000 to 2010 from 5,939,000 to 7,588,000 
respectively(Go, Mozaffarian et al. 2013).  The National Heart, Lung, and Blood Institute 
estimate that the prevalence of cardiovascular disease in the United States in 2012 was 
82.6 million or 26% of the population (NHLBI 2012). 
Coronary heart disease is a form of cardiovascular disease where a narrowing or blockage 
of the artery occurs usually through the build-up of plaque.  Though, coronary heart 
disease prevalence is estimated to account for only 19.7%, 16.3 million, of the 82.6 
million people with cardiovascular disease; coronary heart disease accounts for 49.9% of 
the total deaths for cardiovascular disease.  The total deaths for cardiovascular disease in 
2008 were just under 812 thousand people (NHLBI 2012).  The treatment of coronary 
heart disease typically includes the reducing of symptoms through lifestyle changes 
(healthy diet, maintaining a healthy weight, and managing stress), the use of medications 
(anticoagulants, anticlotting medicines, ACE inhibitors, and beta blockers), and surgical 
procedures (angioplasty with or without the use of a stent, and coronary artery bypass 
grafting).  This thesis will focus on the use of vascular stents, where in 2010 alone 454 
thousand coronary artery stent implantation surgeries were performed in hospitals across 
the United States(NHDS 2010). 
A major problem with the use of vascular stents is the occurrence of restenosis.  
Restenosis is defined as the renarrowing of the artery due to the formation of scar tissue 
and can occur once a vascular stent has been implanted.  The current gold standard for 
preventing restenosis is to coat the vascular stent with drugs, such as Rapamycin, that 
will block the onset of restenosis.  This method has shown to be such a success that in   
2010, 75% of the stents implanted during percutaneous coronary intervention were drug-
eluting stents compared to bare-metal stents(Go, Mozaffarian et al. 2013).The progress of 
drug-eluting stents has provided a great improvement in preventing restenosis in, but 
restenosis, though reduced, is still present in drug-eluting stents.  More research needs to 
be done to fully prevent restenosis from developing in vascular stents implantation.  
Research in electrospinning with the incorporation of growth factors has shown to be one 
of these methods in preventing restenosis from occurring (Zhang, Jia et al. 2013).  The 
covered-stent provides a cushioned barrier between the harsh metal and the endothelial 
layer of the damaged blood vessel.   
Our hypothesis is that a polyurethane covered-stent, electrospun with a solution of HFP, 
can be placed under extreme physiological conditions, and can be used as an effective 
drug carrier in the prevention of restenosis.  When implementing and deploying a bare-
metal stent, the endothelial lining can become damaged.  This will expose the sub-intimal 
matrix stimulating platelets which will lead to the release of growth factors, and the 
growth of smooth muscle cells leading to hyperplasia and restenosis.  Electrospun 
polyurethane fibers containing Rapamycin has been shown to reduce the growth of 
smooth muscle cells (Han, Farah et al. 2013).  This thesis will then focus on quantifying 
the water leakage of the polyurethane covered-stent when placed isolated flow 
conditions.  
  
Chapter 2: Specific Aims 
 
Specific Aim 1: Design a flow system that will quantify fluid leakage while isolating 
flow conditions such as pressure, flow speed, and amplitude of oscillation. 
Specific Aim 2: Quantify the water leakage of electrospun polyurethane covered vascular 
stents under physiological and pathophysiological conditions 
  
Chapter 3: Background 
 3.1: Restenosis 
One of the main surgical methods for the treatment of coronary heart disease is the 
implementation of a vascular stent.  The standard practice of this procedure is to have a 
thin flexible catheter with a balloon attached to the tip.   Over the deflated balloon tip of 
the catheter, a vascular stent is crimped ensuring the stent is securely attached to the tip 
of the balloon.  The stent and balloon are then inserted into the body, usually through a 
femoral incision, and passes through the artery until reaching the targeted narrowed 
section of blood vessel.  The balloon catheter is then inflated, deploying the stent, and 
widening the narrowed blood vessel (Hanekamp, Koolen et al. 1999). 
One of the long term adverse effects of the vascular stents and balloon catheter is onset of 
restenosis, a renarrowing of the blood vessel once the stent has been deployed.  This 
effectively necessitates repeated surgery, with stent restenosis occurs in around 15-20% 
for “simple” coronary lesions, and in 30-60% of patients with complex lesions.  Repeated 
surgeries come with increase cost and risk, making restenosis one of the major limitations 
to stent implementation (Fattori and Piva 2003).   
Restenosis arises when the expansion of the stent causes injury to the endothelial lining 
of the artery (Figure 1).  This injury results in the release of platelet-derived growth 
factors.  These platelet-derived growth factors stimulate the proliferation of smooth 
muscle cells by initiating the DNA synthesis and cell division by up-regulating the 
protein kinases through the mTOR pathways.  The cell then moves from the arrest state 
(G0) to the active cell cycling (G1) state.   Once in G1 state, a second group of growth 
factors, known as progression factors, allows the smooth muscle cells to enter the DNA 
synthesis (S) phase.  The continued synthesis of the smooth muscle cells DNA leads to 
the proliferation of the smooth muscle cells.  Along with this proliferation, platelet-
derived growth factors are also chemotactic, allowing for migration of smooth muscle 
cells from the local media layer of the artery into the intimal layer comprised of 
endothelial cells.  This attraction is not limited to only smooth muscle cells, but also to 
activated macrophages, which along with the surrounding endothelial cells produce more 
platelet-derived growth factors (Liu, Roubin et al. 1989).  This creates a positive 
feedback cycle resulting in the increased proliferation of the smooth muscle cells. 
Due to this increased proliferation of the smooth muscle cells, the damaged intimal layer 
becomes compromised in its ability to maintain proper vessel morphology.  Two to three 
days after injury many of the smooth muscle cells have entered into a proliferative state.  
The vast majority of this increased growth is completed within the first week, while 
populations of non-dividing smooth muscle cells remains constant.  This post injury 
smooth muscle cell growth peaks around two weeks after injury and remains localized to 
the injury sight.  The smooth muscle cell population numbers then remain constant to up 
to a year after injury.  This would mean that the thickening of the cell wall is due to the 
increased cell volume of smooth muscle cell and synthesis/accumulation of extracellular 
matrix and connective tissue(Liu, Roubin et al. 1989).The thickening of the cell wall 
leads to the eventual renarrowing of the blood vessel, restenosis. 
 Figure 1: Illustrated mechanism for restenosis.  The damage to the endothelial lining releases platelet derived 
growth factors causing smooth muscle cell growth leading to a decreased lumen diameter(Liu, Roubin et al. 
1989). 
 
 3.2:Bare-metal/drug-eluting/covered stents 
Bare-Metal 
Modern stents can be placed into two different categories called closed- and open-cell 
configurations.  Closed-cell configuration stents are stents that, due to their structural 
design, after expanded do not change the area size of a single cell when flexed.  Open-
cell configurations are just the opposite where after expansion the area of individual cells 
do change when flexed.  Many drug eluting stents generally use closed-cell 
configurations because the drug concentrations should not change in any area on the stent 
even when the stent is curved (Hara, Nakamura et al. 2006).    
 
Figure 2: Closed vs. Open Cell Design.  Closed cells give the same cell area despite the flexing of the stent.  Open cell 
design alters the cell size based on the flexing of the stent.  Image adapted from Rogers CD (Rogers 2005). 
 
Typically stents are constructed with either 316L stainless steel or cobalt-chromium 
cobalt alloys as these metals provide the structural support to allow thin struts to be 
produced, are corrosion resistant, and have a high biocompatibility due to low ion release 
(O'Brien and Carroll 2009).  The incorporation of platinum has been shown to have a 
positive aspect on the growth of endothelial cells on bare metal stents, while maintaining 
the structural integrity of the struts (O'Brien, Stinson et al. 2010).   
Bare-metal stents have increased over the years because it has shown to have an increase 
in procedural success when compared to balloon angioplasty.  In a study of 410 patients 
with symptomatic coronary disease, patients with the coronary stent showed a 96.1% 
success rate compared to 89.6% success rate of those with balloon angioplasty.  Also, the 
change in diameter in the lumen had a larger increase (1.72 ±0.46 vs. 1.23 ±0.48 mm), 
and the lumen remained larger (2.49 ±0.43 vs. 1.99 ±0.47 mm) immediately following 
the procedure.  Six months after the procedure, those patients with a bare-metal stent 
continued to have a larger lumen diameter (1.74 ±0.60 vs. 1.56 ±0.65 mm, P = 0.007),and 
a lower rate of restenosis (31.6 percent vs. 42.1 percent, P = 0.046) than those treated 
with balloon angioplasty(Fischman, Leon et al. 1994).Another study with 452 patients 
showed similar results with restenosis rates being 22% and 37% respectively (Betriu, 
Masotti et al. 1999).   It is from this increased efficiency that 80% to 90% of the 
percutaneous coronary interventions now use a vascular stent over  a balloon angioplasty 
(Chen, John et al. 2006).   
While the use of a bare-metal stent has shown to have a lower restenosis rate then balloon 
angioplasty, restenosis still remains a problem.  Bare-metal in-stent restenosis ranges are 
still 20% to 40% at 6 months depending on patient co-morbidities, vessel size, and lesion 
complexity (Babapulle and Eisenberg 2002).   In order to reduce the rate of restenosis a 
coating or cover is placed over the metal that will reduce injury to the endothelial lining, 
or stop the onset of proliferation of smooth muscle cells.    
Drug-Eluting Stents 
Drug-eluting stents have shown to be superior to bare-metal stents in that they not only 
provide mechanical support to the localized tissue and increased blood flow, but they also 
offer the additional benefit of a localized pharmacotherapy for inhibiting in-stent 
restenosis.  Some of the more common drugs used in coating the stents have been 
sirolimus or paclitaxel (Sabate, Jimenez-Quevedo et al. 2005),(Kastrati, Mehilli et al. 
2005).  Clinical evidence has shown that both of these drug coatings have shown to be 
more beneficial when compared to simple bare-metal stents (James, Stenestrand et al. 
2009). 
Sirolimus is an immunomodulator belonging to the limus family.   These inhibitors have 
a very near lipophilic chemical structure.  The chemical structure allows for the drug to 
bind to the major cytosolic receptor (FK binding protein 12) forming a complex which 
then binds to the cellular target.  The effects of this binding include the blocking of the 
p70S6 kinase pathway and increasing the Cyclin Kinase inhibitor p27kip1 regulators 
(Braun-Dullaeus, Mann et al. 2001).  This results in the cell cycle no longer going from 
the G0 to the G1 phase stopping to proliferation and migration of the smooth muscle cells 
(Poon, Marx et al. 1996). 
Paclitaxel is a lipophilic molecule that stops the proliferation and migratory of smooth 
muscle cells.  It stops the smooth muscle cells from proliferating because the paclitaxel 
drug is a microtubule-stabilizing agent allowing for the increased formation of 
microtubular polymerized structures.  The increase in polymerized structures decreases 
the concentration of tubulin needed for new microtubule formation (Liuzzo, Ambrose et 
al. 2005).  The microtubules are needed in the construction of the mitotic spindle, a key 
component for cellular division (Abal, Andreu et al. 2003).  With the decrease in 
microtubules, the mitotic spindles cannot be formed impeding the growth factor-induced 
DNA synthesis during the M phase of cellular proliferation.  This will ultimately lead to 
apoptosis or cell death.  This means that paclitaxel is a primarily cytotoxic drug (Wang, 
Wang et al. 2000). 
 Figure 3: Primary mechanisms of action of pharmacological agents: Sirolimus and paclitaxel(Papafaklis, 
Chatzizisis et al. 2012). 
 
Coating the drug onto the stents can involve a direct method where the drug is applied to 
the stainless steel stent.  A direct method can be achieved by using a sandblasted stainless 
steel stent.  The sanding will allow for a microporous surface to occur permitting the drug 
to attach to the surface.  The benefit of the mechanical surface treatment is it does not 
lead to any compositional changes to the material.  The drug is then applied to the stent 
using a disposable cartridge.  The cartridge will have a reservoir with a fixed volume for 
the drug, and a spray-ring nozzle to allow even coating of the drug.  The stent surface is 
then dried by removing any ethanol with pressured air (Wessely, Hausleiter et al. 2005).  
This is one of the many ways for creating an effective yet simple drug coated stent. 
Alternatively, a carrier vehicle matrix can be utilized to produce a drug-eluting stent. The 
drug is placed inside a polymer coating, such as poly-l-lactide-co-caprolactone, and the 
polymer is attached to the stent.  This allows for a controlled release of the drug as the 
polymer degrades over time.  An air brush layering technique can be employed where the 
base layer contained the drug and biodegradable polymer solution with a controller box 
having fixed coating and drying periods. Then vacuum dried to remove any residual 
solvent.  Finally, a drug-free top layer can be coated on to prevent any immature drug 
release (Raval, Parikh et al. 2010).  While the carrier vehicle matrix drug coated stent is a 
more complicated method for creating a drug-eluting stent, it would allow for a 
controlled drug release. 
Drug-eluting stents have been shown to reduce the rate of restenosis when compared to 
bare metal stents(Sabate, Jimenez-Quevedo et al. 2005), but in-stent restenosis still 
occurs in 18 to 20.6% of patients (Lotan, Meredith et al. 2009; Alfonso 2010).Poor re-
endothelialization, late stent thrombosis (formation of a blood clot inside of a blood 
vessel), as well as delayed healing are some of the other problems associated with drug-
eluting stents(Jimenez-Valero, Moreno et al. 2009),(Farb, Heller et al. 2001).  This 
demonstrates that while drug-eluting stents have shown progress, many problems still 
need to be addressed before they can become an optimal solution. 
 
Covered-Stents 
Originally designed to prevent aneurysms and seal ruptured arteries, covered stents have 
a thin membrane sleeve that can cover either the lumen, outer surface, or both of the 
metallic stent scaffold.  Once the stent is deployed, the sleeve membrane decreases the 
radial pressure of the stent, and seals the endothelial layer of the lumen from the blood 
stream.  The physical barrier of the membrane prevents late tissue ingrowth and 
restenosis, decreases embolization during stent deployment by trapping debris, acts as a 
reservoir for antithrombic drugs, and seals any perforations(Satler and Mintz 2000). 
There are seven factors that can contribute to the success of a covered stent.  1) The stent 
should have to ability to compress over a small size balloon catheter, and maintain its 
compressed size until deployment. 2) The stent should be flexible so that it will be able to 
reach the targeted area. 3) The stent should have predetermined expandability and little 
recoil.   Elasticity is an important for the membranes because extensive dilation of the 
covered-stent can cause it to recoil.  This recoil can cause malapposition, the poor 
position of the stent against the interior wall, and late stage thrombosis from lack of 
coverage. 4) A low deployment pressure can enhance the risk of injury to the vessel wall. 
5) The covering material should be able to withstand high pressures so that it will not 
tear.  6) A low-water permeable membrane to seal the perforated artery and prevent the 
ingrowth of an aneurysm. 7) The sleeve should allow biomimetic peptides, antibodies, 
and growth factors to be incorporated into the structure for localized delivery (Pant, 
Bressloff et al. 2012), (Bajaj, Parikh et al. 2010), (Thierry, Merhi et al. 2005), (Jamshidi, 
Mahmoody et al. 2008). 
The materials used to design the covered stent membranes can be placed into two 
different categories, synthetic and biological.  Synthetic materials would include 
polymers such as polyurethane, Polyethylene terephthalate, and Polytetrafluoroethylene.  
Polyurethane has shown to be biocompatible, elastic, and excellent for endothelialization, 
while still be biodegradable.  Polyethylene terephthalate shows high tensile strength, but 
is susceptible to thrombosis, generates fibrous capsules, and is not suitable for small 
caliber conduits.  Polytetrafluoroethylene is durable and biocompatible, but has low 
flexibility and requires high post-dilation pressure (Farhatnia, Tan et al. 2013).  The 
benefits to a synthetic polymer allow for the material to have a quality control, a lower 
cost in its production, and are easier to fabricate. 
Natural fibers have shown to have an increased biocompatibility, faster 
endothelialization, and an incorporation of the structures into the vessel wall with a 
similar compliance to surrounding native tissue (Goodwin, Yoon et al. 2000).  Natural 
fibers can include chitosan, collagen, and fibrin based polymers.  Chitosan is a non-toxic, 
non-immunogenic, antimicrobial, bioadhesive.  However, when in contact with blood, 
chitosan can stimulate thrombosis and embolization unless blended with a water soluble 
polymer.  Collagen fibers allow for rapid endothelialization, but long term studies are still 
needed to access stent performance over time.  Finally, fibrin has little tissue reaction and 
has the potential to act as a drug delivery vehicle, but the mechanical properties will need 
to be improved to be able to produce an effective covered-stent (Farhatnia, Tan et al. 
2013). Each one of these fiber materials can be utilized to construct a membrane for the 
stent, depending on the target needs. 
Along with a variety of polymers, covered-stents can be manufactured using a number of 
techniques.  Electrospinning, discussed in detail below, utilizes a high voltage to generate 
an electrically charged jet of polymer solution to create nanofibers (Nagai, Nakayama et 
al. 2009). Layer-by-layer assemblies involve the deposition of oppositely charged 
polymers through an electrostatic coating.  The charged interactions form a single thin 
membrane a few micrometers thick.  Solvent-castings are created by immersing a 
stainless steel mandrel with the stent attached into a mold filled with polymer.  The rod is 
then rotated a constant rate to control the thickness of the dip-coating(Gordon, Fishbein et 
al. 2008).  These different methods can be tailored to the desired qualities of the covered-
stent.   This allows for a variety of different types of covered-stents to be manufactured.   
3.3: The Electrospinning Process 
Electrospinning is a method that can be used in the creation of covered stents.  Through 
the use of electrospinning, continuous strands of fibers ranging in diameter from the 
submicron to the nanoscale size can be fabricated(Greiner, Wendorff et al. 2006).   While 
the fabrication of nanofibers is not limited to only electrospinning process, Fiber 
extrusion (Kew, Gwynne et al. 2011) and template synthesis (Ikegame, Tajima et al. 
2003)being some of the many alternatives.  The problem is that many of these processes 
do not have the same versatility or flexibility for fiber production as electrospinning, or 
require a complex set-up.  The typical laboratory set-up for a simple electrospinning 
station on requires a high-voltage power supply, a syringe, a conductive target plate, and 
a flat-tip needle (Teo and Ramakrishna 2006).  At the same time, fibers from 
electrospinning can be produced from many different types of polymers, both synthetic 
and natural (Kowalczyk, Nowicka et al. 2008).  
The electrospinning set-up starts with using the high-voltage power supply to generate an 
electrostatic potential between the flat-tip needle and the conductive target plate.  A fluid 
solution is placed into the syringe and is slowly pumped through the flat tip needle.  The 
solvent of the solution evaporates while the stream travels from the flat tip needle, held at 
a high voltage when connected to the power supply, to the collection plate which it 
typically grounded.  The critical voltage needed for a fiber to be produced typically exists 
between 5,000 and up to 30,000 volts (Burger, Hsiao et al. 2006; Teo and Ramakrishna 
2006), and the conductive target plate can be placed up to 50 centimeters away from the  
needle (Beachley and Wen 2009). It should be noted that the polarity can be reversed 
with this set-up allowing for the collection plate to hold the electrostatic potential while 
the flat-tipped needle is grounded.  Figure 4 shows an image of the basic set-up described 
above. 
 
Figure 4: Typical electrospinning set-up with a grounded  
target and charged needle (Teo and Ramakrishna 2006). 
 
At the tip of the flat-tipped needle, the solution droplet is held in place by the surface 
tension of the solution.  When the solution becomes charged the interactions of the 
electrical charges of the fluid with the electrostatic field forces the solution to form a 
conical shape called a Taylor cone (Yarin, Koombhongse et al. 2001).  When these 
interactions overcome the surface tension of the fluid, the droplet becomes unstable and 
the liquid is ejected from the tip of the needle.   Once this ejection occurs, the droplet is 
allowed for relax slightly; and a steady stream is continuously seen.  The stream increases 
the surface area greatly and allows for the solvent to evaporate more quickly, allowing 
for the solute to collect on the target plate (Burger, Hsiao et al. 2006).   Figure 5 below 
shows the formation of the Taylor cone and stream.   
 
Figure 5: The charge build up at the needle in a basic electrospinning set-up with (a) showing the formation of the 
Taylor cone, (b) the initial ejection of the stream, and (c) the relaxation of the cone with continual stream ejection 
(Burger, Hsiao et al. 2006). 
 The set-up for the electrospinning apparatus plays an important part into the collection of 
the nanofibers.  When positively charged, the fibers will be drawn to any negatively 
charged or grounded, generally metallic, object in the near vicinity.  By introducing a pair 
of metallic rings that were evenly spaced between the needle, and charged with the same 
polarization, the deposition area of the fibers can be significantly reduced (Deitzel, 
Kleinmeyer et al. 2001).  This method allows a controlled deposition and localization of 
the fibers, which have a tendency to deposit in areas outside of the targeted due to 
residual charge build up, and the chaotic movement of the electrospinning jet.   
The electrospinning set-up can also be changed by replacing the flat target shown in 
Figure 2, with a spinning mandrel.  With a spinning mandrel as the target, the fibers will 
deposit onto the surface on the mandrel just as it would on the flat surface plate.  With a 
use of a large diameter mandrel the surface area of the target is increases.  This allows for 
the nanofibers to be distributed over a larger area, and can increase the size of the fabric 
with a fairly consistent thickness(Kim, Lee et al. 2004).  The rate of rotation of the 
mandrel can also affect the fiber orientation on the target.  At speeds below 500 rpm, a 
mix of collagen fibers has been shown to be collected onto the target, but when the 
rotation of the mandrel increased to 4,500 rpm the collagen fibers became orientated to 
along the axis of rotation (Matthews, Wnek et al. 2002).  Figure 4 shows the set-up used 
for electrospinning nanofibers with a spinning mandrel used as the target.  Similar to 
image shown in Figure 2, a reservoir holds the solution until it is pumped through the 
needle.  The needle is connected to a voltage supply positively charging the solution at 
the tip of the needle.  The differences are shown that the fibers adhere not to a grounded 
flat plate target, but to a spinning mandrel.  In this case the mandrel has also been 
negatively charged to further attract the nanofibers. This set-up has been demonstrated to 
as an effective method for producing vascular grafts (Huang, Geng et al. 2012),(Sato, 
Nakazawa et al. 2010).These are a few ways that electrospinning design set-ups have 
been specialized to alter the design of the nanofiber layout, and there are many other 
methods that can be used to produce a variety of effects on the spinning of the nanofibers 
(Teo and Ramakrishna 2006).    
 
Figure 6: Diagram of Electrospinning set-up where a rotating  
mandrel is used as the target(Matthews, Wnek et al. 2002). 
 
  
   
Chapter 4: Overview of Experimentation 
Ephesos, 316LVM coded, stainless steel stents (length=18 mm, undeployed diameter = 
1.4 mm, deployed diameter = 4 mm), provided by Alvimedica Medical Technologies, 
Inc. (Istanbul, Turkey), were electrospun for either 6 minutes, 8 minutes, or 10 minutes 
with Biospan® segmented polyurethane (SPU) as described in the process of 6.1: 
Electrospun-Coating of Vascular Stents.  Once the stents were electrospun and fully 
coated with the SPU they are deployed into a Tygon® tubing (length =50 cm, internal 
diameter = 4 mm, external diameter= 5.5 mm), and placed into the custom designed leak 
chamber described in 5.3 Leak Chamber Attachment.   
Once the stents are secured into the leak chamber the chamber is attached to the Tissue 
Growth Technologies (TGT) LumeGen multichamber bioreactor.  The reservoir for the 
TGT LumeGen bioreactor is filled with either deionized and distilled water or a 
polyvinylpyrrolidone (PVP) solution described in 6.3: Polyvinylpyrrolidone Solutions.  
The TGT LumeGen bioreactor is turned on, and the initial conditions for evaluating each 
variable, shown in Table 1: Identifies the initial conditions for each experiment.  Each 
condition remains constant throughout each set of measurements unless an “X” is shown.  
The "X" indicates a measured variable within the experiment.are placed into the system.  
As the water or PVP solution cycles through the TGT LumeGen bioreactor, some will 
leak out through the stent where it is collected into a graduated cylinder and measured.   
The measurements at different initial conditions are then analyzed through the methods 
described in 6.4: Data Analysis.   
  
Chapter 5: Design Component 
 5.1: Statement of Design Challenge 
When evaluating vascular stents, it is important to be able to quantify how well these 
stents are to stop blood from hemorrhaging out of the body when either an aneurysm 
bursts or trauma to the artery occurs causing a puncture wound.  This way when vascular 
stents made with either novel materials or unique methodologies can be objectively 
compared to current standards.  For this reason a design was needed that could effectively 
measure the amount of fluid leakage coming out of the stents, while simultaneously 
providing a controlled environment similar to the human body.    
In order for this design to be a success, the fluid passing through the lumen of the stent 
would need to remain separated from the fluid that has passed through the stent 
membrane.  Further, any and all fluid that passes through the stent membrane will need to 
be collected and measured.  The in vitro environment that the stents are exposed to 
should mimic the physiological conditions present in the human body.  Parameters for 
mimicking the physiological conditions in vitro include average pressure, average 
volumetric flow rate, flow oscillation (both frequency and amplitude), and viscosity of 
fluid.  Finally, if possible, adjusting any parameter should be decoupled from the other 
parameters.   Decoupling the parameters from each other allows for the user to set the 
initial conditions over a range of values.  This will allow the design to mimic not only the 
ideal physiological conditions, but pathophysiological conditions as well. A successful 
design is made when each of these criteria is met both consistently and repeatedly. 
5.2 Preliminary Flow Design 
The first design used was inspired by a similar design developed by (Kuraishi, Iwata et 
al. 2009).  A schematic for the preliminary design is shown below.   Three similar 
designs were made with different PVC piping lengths to provide a constant pressure of 
either 60 mmHg, 90 mmHg, or 120 mmHg.   
 
Figure 7: Schematic for continuous flow system 
 
The design functions by having the bottom Tygon® tube clamped off between the PVC 
pipe and the stent.  Then water fills the PVC pipe until it starts to drain from the top exit 
tube, ensuring the pressure has built to the desired levels.  The clamp is removed, and the 
inflow water levels are adjusted so that both water and air can be seen constantly draining 
from the top exit tube, while pressurized water is seen exiting the bottom tube.  This 
ensures that the pressure remains constant throughout the entire experiment.  Any water 
leaking from the vascular stent was collected into a graduated cylinder and measured.   
The reason for being only a preliminary design is that the constraints of this system does 
not allow for much flexibility in adjusting pressure levels, nor is the fluid flow portrayal 
an accurate physiological representation.   In order to adjust pressure levels, an entirely 
new setup needed to be constructed.  This eliminates the possibility for the vascular stents 
to smoothly transition from a lower pressure level, 60 mmHg, to a higher pressure level, 
120 mmHg, and restricts the system to only allow a continuous flow pattern rather than a 
pulsatile flow which would be more reflective of the body.   
More importantly however is the fluid flow rate through the system.  The volumetric flow 
rate for water, measured using a Transonic® Flowprobe, was between 400 and 600 
ml/min (flow speed of 53 and 80 cm/s respectively).  This volumetric flow speeds were 
well above normal biological conditions (flow speed for the aorta is 40 cm/s) causing an 
excessive amount of shear stress on the vascular stent.  Finally, due to the linear flow 
design of the system, an excessive amount of drainage for the fluid was produced.  This 
was done to the point that only water could be used practically as a fluid source.  The 
results below will discuss the difference between water and more viscous substances such 
as blood.   
A new system was needed to could reduce the flow speed to be more reflective of 
biological conditions, allow for different viscous substances to be used, would allow for a 
smooth transition between different pressures, and ideally would not produce much 
drainage waste.   
 5.3 Leak Chamber Attachment 
To allow for precise control over flow rate and pressure values, a Tissue Growth 
Technologies (TGT) LumeGen multichamber bioreactor was modified.  The original 
setup for the TGT bioreactor (Figure 8) is a close loop pulsatile pump bioreactor.  The 
main components for the system include a reservoir, a peristaltic pump, a stimulator 
pump, test chamber, and a restrictor valve with a computer controlled interface.  
The reservoir (Figure 8 blue) holds the supply of fluid needed to pass through the system.  
It has an outflow tube, an inflow tube, and an air tube with an Aerodisc® PF syringe 
filter.  The air tube and filter allow for the reservoir to maintain atmospheric pressure at 
all times.  The inflow and outflow tubes, when connected to the peristaltic pump, allow 
for the fluid to travel through the rest of the pulsatile system.  The same amount of fluid 
flowing out of the reservoir is pumped back in allowing the reservoir to maintain a 
consistent volume level.  This means that by using a reservoir the fluid is continuously 
recycled through the system reducing the amount of fluid needed and eliminating any 
waste.   
The MasterFlex® pump (Figure 8 orange) provides the primary power mechanism to 
pump the fluid through the flow system.  The MasterFlex® pump is a peristaltic pump 
allowing for an oscillatory volumetric flow rate.  With just the MasterFlex® pump and 
reservoir the flow systems allows for a closed loop oscillatory flow.  Limitation of this 
system is that both pulsatility and pressure are dependent on the volumetric flow rate.  
The equations below show the relationship between pressure and volumetric flow rate.  
The first equation shows the relationship between volumetric flow rate and flow speed. 
   
  
   
 
 v = Flow Speed  
 q = Volumetric flow rate 
 D = inner diameter of the tube 
 
The second equation shows the relationship between pressure and flow speed.    
   √
  
 
 
v = Flow Speed 
 P = Pressure 
 ρ = density of the fluid 
 
 Both equations can then be combined to create the equation 
  
  
  
   
  
 
 
The relationship from the equation shows that as the volumetric flow rate increases, the 
pressure will increase; and if the volumetric flow rate decreases, the pressure will 
decrease.   
The oscillation is also dependent on the volumetric flow rate from the construction of the 
peristaltic pump.  The motor of the MasterFlex® pump moves the rollers of the pump.  
The rollers constrict the tubing and force the fluid through the tube.  With each roller 
constricting and forcing fluid through a pulse or wave of high pressure is generated.  The 
repetition of pulses allows for oscillatory flow through the system.  With the volume of 
fluid in each pulse being the same, in order to increase volumetric flow rate, the rate the 
rollers constrict and release a pulse of fluid is increased.  This increased rate in pulses 
increases the oscillation of the flow system.   In order create a system where both the 
pulsatility and the pressure levels are independent of the volumetric flow rate, more 
components were needed to be introduced.   
The introduction of a restrictor valve (Figure 8 red) allows for the decoupling of the 
pressure values and the volumetric flow rate.  The restrictor valve works by closing the 
valve, the diameter of out-flowing fluid tubing is decreased at the restrictor valve.  The 
volumetric flow rate remains constants from the MasterFlex® pump.  The decrease in 
diameter of the tube, as shown in the equation above, increases the pressure of fluid.  The 
pressure builds in the section of tubing from the restrictor valve to the MasterFlex® 
pump.  The opposite is true as well where by opening the restrictor valve, the diameter is 
increased, and the pressure is decreased.  Thus, the incorporation of a restrictor valve 
allows for the independent control of the pressure levels with a constant volumetric flow 
rate generated from the MasterFlex® pump. 
As the incorporation of a restrictor valve allows for independent control of the pressure 
levels, the stimulator pump (Figure 8 green) allows for independent control of the 
pulsatile oscillation.  The stimulator pump is a hydraulic piston, and operates using the 
same principle equation 
 
 
  
 
 
 
P = pressure 
 F = applied force 
 A = area 
As the piston pushes into the fluid, it increases the amount force applied to the fluid.  
This then increases the pressure.  As the piston lowers, it decreases the applied force, and 
thus decreases the pressure of the fluid.  A computer interface allows for the piston to 
increase and decrease in a precise and accurate level.  This interface, when combined 
with the MasterFlex® pump, allows for the stimulator pump to work with or against the 
natural oscillation of the peristaltic pump.  The net effect is that the oscillation amplitudes 
and frequencies can be either increased or decreased dependent on the piston position 
with a constant volumetric flow rate.   
The computer program will then allows for each of these components to be integrated 
together.  The digital interface allows for the initial conditions of the system to be set into 
the components on a consistent and repeatable basis.  The computer program also allows 
for the incorporation of sensory data.   With the incorporation of a pressure transducer 
located at the stimulator pump, the digital interface is able to have a continuous input and 
validation of the pressure levels just prior to the sample.  The location of the transducer 
allows for the reading of the net pressure effect after interacting with the MasterFlex® 
pump, restrictor valve, and stimulator pump.  The pressure readings over time can then 
display the pressure levels and oscillation pattern over time.   
Not only does the pressure transducer allow for the validation of pressure levels, but 
because the flow system is controlled through the same digital interface a self correcting 
mechanism can be introduced.  This means that when outside influence alters the pressure 
levels in the system, the flow system can self-correct by altering the position of the 
stimulator pump or rotation speed of the MasterFlex® pump to place the pressure levels 
and flow rate back to the initial conditions.  During this time the interface has recorded 
both the initial disturbance and the self-correction.  An analog flow meter is placed in to 
validate the volumetric flow rate.   
 Finally, the LumeGen chamber is used for testing vascular grafts.  The design of the 
LumeGen chamber was not suited to accurately quantify the leakage of the vascular 
stents, and was replaced with a custom made leak chamber to allow for quantifying the 
leakage of the coated vascular stents.  The criteria for success with the leak chamber are 
to design a chamber that will securely attach to the chamber.  The leak chamber will need 
to seamlessly interface with the rest of the TGT LumeGen flow system, and it will need 
to be able to fully capture and measure any leakage passing through the stent membrane.  
 Figure 8: Flow chart of the Tissue Growth Technologies LumeGen Bioreactor 
 
The leak chamber, made at Drexel Instrument Shop, is composed of polypropylene center 
with two polycarbonate plates covering each side.  The clear polycarbonate acts as a 
window so the stent may be viewed, while ensuring that all fluid is collected.  Both are 
cut into 6 sided shapes (top: 4.5”, bottom: 0.875”, sides: 1.75”, angled sides: ~2.44”) 
where the polypropylene is 0.75” thick, and the polycarbonate is 0.125” thick.  Between 
each polycarbonate plate and the polypropylene core, rubber washers are set to prevent 
any fluid from leaking out the sides.  These are clamped together using four stainless 
steel threaded bar (length: ~1.19, thickness: 0.125”), and eight screw nuts.   
The polypropylene center has a pentagon hole (top: 3”, sides: 1.25”, angled sides: ~1.8”) 
cut from the center to allow for the stent to be placed inside.  The top of the 
polypropylene has a threaded hole0.625” cut through to allow for air to enter, and the 
bottom has the same size hole cut to allow for water to leak out.  Each side has a 
hole0.375” cut to allow for the stainless steel nozzles.  The nozzles allowed for the stents 
to attach and detach from the leak chamber, and allow fluid to pass through the interior.  
The nozzles are secured using a plastic clamp and two screws.  Figure 9 shows a 3D 
model of the completed leak chamber.   
 
Figure 9: A 3D model of the leak chamber 
 
With this design, the leak chamber is capable of capturing and quantifying any leakage 
from the vascular stent.  The stent can be securely attached to the leak chamber, and 
exposed to the LumeGen flow initial conditions.  Finally, the leak chamber is capable of 
interfacing with the rest of the TGT LumeGen system.  The leak chamber can replace the 
LumeGen chamber from the original TGT bioreactor.  Figure 10 shows the flow chart of 
the modified TGT bioreactor.   
The constraints of this system are that it is only able to measure one stent at a time. This 
means that if multiple stents would need to be tested to show a direct comparison under 
identical conditions, an entirely separate chamber would need to be constructed.  Finally, 
the inside of the leak chamber is exposed to the atmosphere. This means that sterile 
conditions are difficult to create and cannot be maintained over a long period of time. The 
net result is that adding a biological component such as seeding the stent with endothelial 
cells would likely result in contamination.  
 
Figure 10:Modified TGT LumeGen Bioreactor flow chart 
 
This modified TGT bioreactor allows for any fluid that passes through the stent 
membrane to be collected and measured.  The MasterFlex® pump, restrictor valve, and 
stimulator pump enables the pressure, volumetric flow rate, flow oscillation (both 
frequency and amplitude) to be decoupled from each other, and able to set a variety of 
initial conditions. The design of the system also allows for fluids of different viscosities 
to be placed in the reservoir.  With these parameters can mimic the physiological and 
pathophysiological conditions of the body in vitro, while collecting any water leakage 
from the stents.  
  While the design of this modified TGT LumeGen bioreactor does successfully meet the 
criteria, there are still limitations with the system. As mentioned above, the leak chamber 
is exposed to the atmosphere leaving the chamber vulnerable to becoming contaminated 
if a biological component is introduced.  This problem is compounded because the leak 
chamber is interconnected to the rest of the flow system, thus exposing the risk of 
contaminating the entire flow system.  Sterilizing and maintaining a sterilized 
environment would be extremely difficult with this design, if a biological component 
would need to be added.  The second limitation is that while each component of the flow 
system (MasterFlex® flow pump, restrictor valve, and stimulator pump) are capable of a 
range in values, that range is limited.  The MasterFlex® flow pump has a limit to how 
fast it can pump fluid (290 ml/min), the restrictor valve has a limited resolution in valve 
adjustment producing a incremental stepping pattern for small adjustments instead of a 
smooth continuously increase, and the piston for the stimulator pump has a limit in 
displacement limiting the level of pressure generation (160 mmHg). Finally, while the 
complexity of the system allows for independent control of the pressure, volumetric flow 
rate, and oscillation when setting the initial conditions, these parameters are still 
dependent on each other throughout the duration of the experiment.   This means that if 
one of the components begins to fail (and the other components are unable to compensate 
for the malfunction/external disruption) the entire flow system will go into a chaotic state 
and eventually crash. This can cause a great deal of time to reset/repair the system, and 
severely limits its robustness. 
  
Chapter 6: Materials and Methods 
6.1: Electrospun-Coating on Vascular Stents 
Coating the vascular stents, a process developed by Gozde Senel-Ayaz and Jinjia Han, 
was done by creating a solution of Biospan® segmented polyurethane (SPU) and 
1,1,1,3,3,3-Hexaflouro-2-propanol (HFP).  A 5% (w/v) solution was prepared by 
dissolving the SPU, from DSM Biomedical (Berkeley, CA, USA), in HFP (cat no. 
H0424), purchased from TCI America (Portland, OR, USA).  The solution was stirred 
overnight at temperatures between 20
o
C and 25
o
C.   
A vertical electrospinning apparatus (Figure 4 above) with a power supply (ES30-0.1N, 
High Voltage Research, Ormond Beach, FL, USA) set to 15 kV generates an electric 
field between a syringe needle and a stationary metal target at a distance of 12 cm.  The 
syringe pumps the SPU solution at a rate of 0.8ml/h by an infusion pump (Fusion 100, 
Chemyx Inc., Stafford, TX, USA) through a blunt 18-gauge stainless steel needle. 
Between the needle and the target a stainless steel stent (Ephesos, L=15 mm, D = 1.4 
mm), provided by Alvimedica Medical Technologies, Inc. (Istanbul, Turkey), was slide 
onto a mandrel (1.5 mm in diameter and 4 cm in length, made at Drexel Instrument 
Shop).  The mandrel was connected to a drill (Bosch Colt© 1.0 HP Palm Router, PR 20 
EVSK, Bosch Tool Corp.,) rotating at 22,500 rpm.  The stents collect the electrospun 
SPU fibers for a period of 6, 8, or 10 minutes, creating a covering over the stent 134+/- 8 
µm, 229+/-6 µm, and 272+/-19 µm thick respectively.  The electrospinning process is 
then turned off, and a razor is used to cut both ends of the stent to separate the stent from 
the mandrel.   
6.2: Coated Vascular Stents under Flow 
In preparation, the Tissue Growth Technologies (TGT) LumeGen multichannel 
bioreactor, is flushed with either deionized and distilled water or a Polyvinyl propylene 
and deionized and distilled water solution (see below solution preparation) at a 
temperature between 20
o
C and 25
o
C using operating protocol (see index).  Once all the 
air bubbles from the TGT LumeGen bioreactor are removed from the system, the motor 
of TGT LumeGen bioreactor is then turned off.  The tubing on both sides of the 
LumeGen chamber are clamped down to ensure that no water or solution leaks out, and 
the LumeGen chamber is removed.   
Tygon® Tubing with an inner diameter of 4 mm and an outer diameter of 5.5 mm is cut 
into 50 mm length pieces.  Then a small circular hole is cut into the center of the tubing 
of either 3 or 4 mm in diameter.  The hole was measured using a standard pair of calipers 
at 6 different points.   
Each coated vascular stent is then deployed in a 5 cm long Tygon® Tubing.  The stents 
are fully deployed using a BasixCOMPAKTM analog inflation Syringe pressed to 10 
ATM/bar attaching the stent to the inside of the Tygon® tube.  The tubing was then 
secured to the nozzles of the leak chamber to by elastic grips.  Once again the inflation 
syringe and balloon catheter were used to ensure that the stent is fully deployed and 
secured to the tubing.   The leak chamber is then attached to a Tissue Growth 
Technologies LumeGen multichannel bioreactor in place of the standard LumeGen 
chamber.   Once the leak chamber is secured to the TGT LumeGen bioreactor, the initial 
conditions are set into the TGT LumeGen bioreactor.  The initial conditions for each flow 
experiment are shown in the table below.   
Experiment 
Electrospun 
Time 
Flow 
Speed 
Avg. 
Pressure 
Amplitude Viscosity 
Puncture 
size 
Electrospun Time X 90 90 30 1cP 3 mm 
Flow Speed 8 minutes X 90 30 1cP 3 mm 
Pressure1 6 minutes 90 X 30 1cP 3 mm 
Pressure2 8 minutes 90 X 30 1cP 3 mm 
Pressure3 10 minutes 90 X 30 1cP 3 mm 
Pressure4 X 90 X 30 1cP 3 mm 
Pressure5 8 minutes 45 X 30 1cP 3 mm 
Pressure6 8 minutes 180 X 30 1cP 3 mm 
Pressure7 8 minutes X X 30 1cP 3 mm 
Pressure8 8 minutes 90 X 30 1cP X 
Pressure9 8 minutes 90 X 30 X 3 mm 
Amplitude1 8 minutes 45 90 X 1cP 3 mm 
Amplitude2 8 minutes 90 90 X 1cP 3 mm 
Amplitude3 8 minutes 180 90 X 1cP 3 mm 
Amplitude4 8 minutes X 90 X 1cP 3 mm 
Amplitude5 8 minutes 90 90 X X 3 mm 
Amplitude6 8 minutes 90 90 X 1cP X 
Saturation over 
Time 
8 minutes 90 90 30 X 3 mm 
Table 1: Identifies the initial conditions for each experiment.  Each condition remains constant throughout each 
set of measurements unless an “X” is shown.  The "X" indicates a measured variable within the experiment. 
 
Once the initial conditions are placed into the TGT LumeGen bioreactor, it will run 
through a standard startup procedure.  Once finished, the leak chamber is placed above a 
measuring cylinder as water or PVP solution is collected and measured for 15 minutes.  
After 15 minutes, the leak chamber is immediately removed and placed over a second 
measuring cylinder.  This is repeated until 5 consecutive measurements are made with 
each sample at each data point.   
6.3: Polyvinylpyrrolidone Solutions 
The goal of creating polyvinylpyrrolidone (PVP) solutions is see how the vascular stents 
behaved under viscous substances higher then water, such as blood.  Water has a 
viscosity of 1 centipoise, while blood has a viscosity of 4 centipoises.  In order to 
determine the correct amount of PVP to add, a viscosity curve was created.  Table 2 
below depicts how much of either water orpolyvinylpyrrolidone power was used to create 
each percent weight solution.  All solutions were made at 20
o
C to 25
o
C, and the PVP 
powder was purchased from Fisher Scientific Lot No. 986724. 
% PVP 
Solution 
PVP 
(gms) 
water 
(ml) 
0 0.00 10.00 
3.5 0.35 9.65 
5 0.50 9.50 
7.9 0.79 9.21 
10 1.00 9.00 
12.4 1.24 8.76 
15 1.50 8.50 
Table 2: Identifies how much PVP or water was used to create each % weight 
 solution used for calculating a viscosity curve for PVP solution 
 
Each solution was then placed in a size no. 1 GILMONT® Instruments falling ball 
viscometer filling the viscometer to the top.  Then, either a glass or a stainless steel ball 
was dropped and timed from when the ball passed between the two red lines at the top of 
the viscometer until it passed between the bottom of the two red lines at the bottom of the 
viscometer.  The time was taken by using a standard stopwatch.  This was repeated five 
times for each solution. 
For the falling ball viscometer, the viscosity is calculated using a simple formula.  
  
 
       
 
K= viscometer constant (0.3 for size no. 1 viscometer) 
μ = viscosity in centipoises 
   = density of the ball (gms/ml) 
         2.53 for the glass ball 
         8.02 for the stainless steel ball 
ρ = density of the liquid (gms/ml) 
t = time of descent (minutes) 
  
The curve generated (see Figure 29), the best fit exponential line of gave the equation 
below with an R
2
 value of 0.987. 
               
µ = viscosity in centipoises  
 x = percent weight PVP in solution 
 
From this equation 400 ml bottles of 2, 4, and 8 centipoise solutions were made.  Table 3 
below shows how much water and PVP powder was used in creating each of these 
solutions. 
Calculated 
Viscosity 
(cp) 
% PVP 
Solution 
PVP 
(gms) 
water 
(ml) 
1 0 0 400 
2 3.4 13.6 386.4 
4 7.6 30.4 369.6 
8 11.9 47.6 352.4 
Table 3: Identifies the amount of PVP and water in each 
400 ml solution to the corresponding calculated viscosities 
 
6.4: Data Analysis 
Analysis of each test, with the exception of the Water Leakage vs Electrospun Time, was 
done using either the 2 variable Anova or the 3 variable Anova.  This was done because a 
simple T Test analysis assumes that each measurement is independent of each other.  
However, each measurement is taken consecutively for 5 measurements with each 
sample.  This means that a systematic sample bias is introduced into the measurements.  
In order to correct this bias, the 2 variable Anova or 3 variable Anova is used. 
The Anova for the bar and Lines graphs are done taking the raw data measurements, and 
subtracting the mean sample value, and adding the overall mean to create the corrected 
value.  The mean sample value is created by averaging every value of that particular 
sample for every data point.  The overall mean is created by averaging every value at 
every data point. The net effect of this method allows for the each data points mean value 
to not change, while removing the standard deviation error created through sample bias. 
The reason that this technique is not applied towards the Water Leakage vs Electrospun 
Time (Figure 11)is because 6 minute, 8 minute, and 10 minute are made using different 
stents.  Thus each data point is made up of different samples, so a simple T Test is 
applied.  The same reason applies towards using a 2 variable Anova for Pressure4 
experiment (Figure 17) instead of using the 3 variable Anova. 
Additionally, using a Matlab program, shown in the index below, a pie chart is rendered 
depicting what percentage each variable contributes toward the causing standard 
deviation.  Accompanying the pie chart a table exists depicting if each variable holds any 
statistical difference with a p < 0.01.    
  
Chapter 7: Results 
Three stents electrospun with thicknesses 134+/- 8 µm, 229+/-6 µm, and 272+/-19 µm 
(totaling nine stents) were placed into the modified TGT bioreactor.   The initial 
conditions for this experiment were set to have an oscillated pressure value of 90 +/- 30 
mmHg with 1Hz oscillation, and a flow rate of 90 ml/min.  Five consecutive 
measurements were taken from each sample, with each measurement lasting 15 minutes.  
Figure 11shows how much water leaked through each type of electrospun stent.   
 
 
Figure 11: Line graph depicts the water leakage vs. electrospun time.  Pie chart indicates what percentage of the 
standard deviation is due to the electrospun time, or simple deviation in results.  Table shows the corresponding 
numerical values. 
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Water Leakage vs Stent Thickness 
Source Sum Sq Probability 
Electrospun 
Time 
1.08 0.62 
Error 47.52 --- 
Total 48.60 --- 
 From Figure 11 the graph indicates that there is no significant difference between SPU 
stents with an electrospun thickness of 134+/- 8 µm, 229+/-6 µm, and 272+/-19 µm.  This 
is correlated with the pie chart and table (Figure 11b and 11c).  Both show that the sum 
square value difference produced from electrospinning times are much smaller than the 
sum square values produced by measurement error.  This gives a p-value > 0.01 stating 
that there is no significant difference between data points. 
When looking at water leakage vs. flow speed, three stents, electrospun for 8 minutes 
each, were used.  Flow speeds ranged from a minimum value of 30 ml/min to a maximum 
speed of 290 ml/min.  The pressure oscillated at 90+/- 30 mmHg at 1 Hz for each data 
point, and five consecutive measurements were taken for 15 minutes each.  
 
 
 
 
 
y = -0.0002x + 1.572 
R² = 0.0086 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 50 100 150 200 250 300
W
at
e
r 
Le
ak
ag
e
 (
m
l)
 
Flow Speed (ml/min) 
Water Leakage vs Flow Speed 
 Figure 12: Graph depicts the water leakage as flow speed increases.  Pie chart gives the sum square values to 
indicate which factors are the cause in standard deviation as a percentage.  Table gives the corresponding 
numerical values and probabilities of significant difference. 
The plot shows the water leakage as flow speed increases.  The plot was done using a 2 
variable anova.  This was done because the measurements were not independent of each 
other due to low sample size.  The anova allowed for the statistical deviation due to 
sample size to be removed.  This was done by subtracting the mean sample value and 
adding the overall mean value.  The pie chart shows that most of the standard deviation is 
caused from variations in the samples.  This is reflected in the table as well showing the 
probability well below the 0.01 threshold.  The table also shows that the flow speed has a 
p-value < 0.01.  While the table does show that some of the individual sample 
measurements are statistically different from each other, the plot shows that this has 
neither a positive or negative correlation in water leakage as flow speed increases. 
To see how the stents changed when saturated in water for an extended period of time, 
three untested stents were placed in the modified TGT LumeGen bioreactor and five 
consecutive 15 minute measurements were made with each stent. Each stent was then 
placed into a conical tube filled with water for 12 hours.  After the 12 hours, the water 
leakage was measured again by placing the stents into the modified TGT LumeGen 
Source Sum Sq 
Probability 
(p-value) 
Flow Speed 1.90 5.32e-5 
Sample 12.28 5.35e-23 
Error 4.93 --- 
Total 19.10 --- 
bioreactor for 15 minutes per measurement, with five consecutive measurements.  This 
was repeated at 12, 24, 36, 48, 60, and 72 hour time points.   
 
 
Figure 13: Top graph shows the decrease in water leakage over the longer they were saturated in water.  The 
standard deviation decreases as well as the stents remain saturated.  The bottom graph shows a zoomed in 
version of the final 5 data points.  It shows that the average leakage plateaus after 36 hours.  Standard deviation 
also plateaus after this time as well. 
 
Figure 13 shows that in the first 36 hours the average amount of water leakage greatly 
decreases.  After the 36 hour period, shown in the zoom in portion of the graph (bottom), 
the average amount of water leakage levels off to a much more consistent value.  Along 
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Hours in Saturation 
Leakage when Saturated in Water over Time (zoomed in) 
with the average water leakage, the standard deviation between the vascular stents at each 
time point decreases as well.  As show in point zero, the standard deviation is 
approximately 18.5 ml, but the standard deviation at 72 hours is closer to 0.01 ml.  This 
gives a more steady and consistent result.  
 
Image 1: Left image depicts an SEM showing a PU covered stent not exposed to flow conditions.  Right shows an 
SEM image of PU covered stent after exposure to pulsatile flow conditions for 72 hours. 
Image 1 shows an SEM image of the polyurathene covered stents.  Both stents have a 
stent thickenss of 229+/-6 µm, and the images are taken at the same level of 
magnification (2,395x) depicting the same size scale bar of 50 μm.  The left image shows 
a covered stent that was never exposed to physiological or pathophysiological conditions.  
The right image shows the SEM image of a covered stent exposed to the conditions 
described in Figure 13.  The fibers in the left image are fully extended and across the 
surface of the vascular stent, and pores areas are visible between the fibers.  The average 
diameter of the fibers ranges between 0.3-0.6 μm.  The fibers in the right image show a 
deformity in the fibers. The fibers are curved, and more entangled within each other.  The 
fibers appear to be in a more relaxed state, and have an average diameter between 1.4 and 
2.5 μm.   
Figure 14 shows the water leakage as pressure increases with the water leakage for the 6 
minute, 8 minute, 10 minute electrospun stents (thickness of 134+/- 8 µm, 229+/-6 µm, 
and 272+/-19 µm respectively) , and the average value. Three samples were used for each 
electrospun time.  Each sample was measured five times consecutively for 15 minutes per 
measurement.  The flow speed remained constant at 90 ml/min.  The average pressure 
was increased by 30 mmHg for each data point, but the oscillation amplitude remained 
+/- 30, where each oscillation was at a frequency of 1 Hz.  The Index provides the 
individual water leakage vs. pressure values for the 6 minute, 8 minute, and 10 minute 
electrospun stents.  The two variable anova was still used in looking at standard deviation 
and p-value.   
 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
30 +/- 30 60 +/- 30 90 +/- 30 120 +/- 30
W
at
e
r 
Le
ak
ag
e
 (
m
l)
 
Pressure (mmHg) 
Water Leakage vs Pressure at different 
electrospun times  
6 minutes
8 minutes
10 minutes
Average
Source Sum Sq Probability 
Pressure  4.53 ~0 
ElectrospunTime 6.11 ~0 
Pressure* 
Electrospun 
Time 
0.55 0.29 
Error 10.80 --- 
 Figure 14: The line graph shows the water leakage as pressure increases for each different electrospun time coated 
stent.  The pie chart shows the what percentage of each variable the standard deviation is composed of.  The table 
shows the corresponding numerical 
When looking at the graph of Figure 14, the standard error shows that there is a 
significant difference between the some of the data points.  The pressures at 30+/-30 
mmHg and 60+/- 30 mmHg indicate no significant difference between them, but the 
90+/- 30 mmHg and 120+/-30 mmHg do show to be statistically different from 60+/- 30 
mmHg as well as each other.   The trend for each electrospun time and the average values 
shows that as pressure increases the water leakage increases.  When looking at each 
individual electrospun time, many of the data points are statistically different from each 
other.  The stents electrospun for 10 minutes (thickness: 272+/-19 µm) showed to have a 
highest leakage, while the stents electrospun for 8 minutes (thickness: 229+/-6 µm,) 
generally showed the lowest leakage.   
The table corresponds with this as the sum square value for pressure does show to have p-
value lower than 0.01.  As pressure values increase the water leakage also increases 
showing a positive correlation between pressure and water leakage.  At the same time 
electrospun times are shown to have p-value < 0.01.    When looking at electrospun time, 
Total 22.59 --- 
the p-value < 0.01 indicates that the different electrospun stents with thickness of 134+/- 
8 µm, 229+/-6 µm, and 272+/-19 µm are statistically different from each other.  Finally 
the crossover variable of pressure*electrospun time, which indicates any relationship 
between pressure differences and electrospun time differences shows no statistical 
difference with a p-value >0.01.   
Figures 15 will show the water leakage as pressure increases with flow speeds at 45 
ml/min, 90 ml/min, and 180 ml/min averaged together.  For each experiment, three stents 
that were electrospun for 8 minutes were used for each flow speed.  Each sample 
measured five times consecutively for 15 minutes per measurement.   The average 
pressure was increased by 30 mmHg for each data point, but the oscillation amplitude 
remained +/- 30, where each oscillation was at a frequency of 1 Hz.   
Similar to Figure 14, Figures 15 shows the water leakage as pressure increases, but 
Figure 15 is able to indicate if the flow speeds of 45 ml/min, 90 ml/min, and 180 ml/min 
have any effect on the increase in pressure.  The water leakage vs pressure for each of 
these flow speeds is shown in the index below.   
  
Figure 15: The line graph shows the water leakage as pressure increases at different flow speeds and average 
flow speed.  The pie chart shows how much of each variable contributes towards the standard deviations.  The 
table shows the corresponding numerical values, and the p-values. 
 
When looking at the line graph of Figure 15, the standard error shows that there is a 
significant difference between the some of the data points.  When looking at the average 
value, the pressures at 30+/-30 mmHg and 60+/- 30 mmHg indicate no significant 
difference between them, but the 90+/- 30 mmHg and 120+/-30 mmHg do show to be 
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Pressure (mmHg) 
Water Leakage vs Pressure at different Flow 
Speeds 
45 ml/min
90 ml/min
180 ml/min
Average
Source Sum Sq Probability 
Pressure 10.02 5.19e-18 
Flow Speed 9.46 5.007e-18 
Pressure*Flowspeed 2.94 5.02e-5 
Sample 6.88 4.63e-14 
Error 15.36 -- 
Total 44.67 -- 
statistically different from each other and 60+/-30 mmHg.  This same pattern corresponds 
with each of the different flow rates as well.  When looking at each individual flow rates, 
many of the data points can be shown to be statistically different from each other along 
with a systematic difference between each flow speed.  A flow speed of 45 ml/min 
generally shows the highest water leakage, and a flow speed of 90 ml/min showing the 
lowest leakage.   
The pie shows that the natural deviation between individual measurements is the largest 
source of difference for the standard deviation.  The next largest are caused by 
differences in pressure, flow speed, and some sample variation.  The table correlates with 
this in the sum squared values.  The table also shows that the p-values for both pressure 
and flow speed are below 0.01.  Once again, as pressure increase the water leakage also 
increases showing a positive correlation between pressure and water leakage.  The p-
value < 0.01 for flow speeds indicates that the different flow speeds of 45 ml/min, 90 
ml/min, and 180 ml/min are statistically different from each other.  Finally, the crossover 
variable of pressure*flow speed, which indicates any relationship between pressure 
differences and flow speeds differences shows statistical difference with a p-value >0.01 
indicating that there is a relationship between flow speed and pressure values. 
 Figure 16: Line graph shows the differences in water leakage as pressure increases when comparing a 4 mm 
puncture to a 3 mm puncture. 
 
When looking at the differences inFigure16 it can be seen that there is a difference in 
magnitudes when looking at the water leakage between a 4 mm puncture, and a 3 mm 
puncture.  The 4 mm stents shows a much higher level of water leakage across all data 
points.  The 4 mm puncture also shows an increase in water leakage as pressure 
increases.  While it may appear that the 3 mm puncture remains flat, the data is the same 
data shown in Index Figure 28.  This means that both the 3 mm puncture and the 4 mm 
puncture show the same trend lines, but 4 mm puncture increases the magnitude of water 
leakage, and difference between pressure changes. 
Figure 17 looks at the differences between pulsatile and continuous flow at a flow speed 
of 45 ml/min, 90 ml/min, and 180 ml/min.  With both pulsatile and continuous flow the 
average pressure remained the same at 90 mmHg.  Continuous flow is achieved by 
keeping this pressure level steady, while pulsatile pressure oscillated between 60 and 120 
mmHg at a frequency of one 1 Hz.   
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Figure 17: Bar graph shows the water leakage of pulsatile flow and continuous flow at different flow speeds.  The 
pie chart shows what percentage each variable contributes towards the standard deviation between data points.  
The chart shows the corresponding numeric 
Figure 17 allows for a direct comparison between the pulsatile flow and continuous flow 
at different flow speeds.  When looking at the bar graphthere is no statistical difference 
between the pulsatile and continuous flow types for each flow speed.  However, when 
looking at the flow speeds, there appears to be a statistical difference between 90ml/min 
and the other two data sets (45 ml/min and 180 ml/min).  This is also shown in the pie 
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Flow Speed (ml/min) 
Water Leakage vs Flow Speed at different Flow Types 
Pulsatile
Laminar
Source Sum Sq Probability 
Flow Type 3.0e-3 0.93 
Flow Speed 57.87 ~0 
Flowtype* 
Flowspeed 
0.02 0.98 
Sample 18.2 ~0 
Error 51.25 -- 
Total 109.14 -- 
chart where the flow speed makes for a significant portion of the deviation in data.  Flow 
type makes up a small portion of the pie chart.  The table shows the corresponding values 
where the flow speed shows a p-value close to zero, showing statistical difference.  At the 
same time the p-value for flow type is 0.93 showing no statistical difference.  The 
crossover variable of Flow type and Flow speed shows that there is no significant 
difference between them with a p-value of 0.98.   
  
 
Figure 18: Bar graph shows the water leakage as amplitude increases.  The pie chart shows what percentage 
each variable contributes towards the standard deviation between data points.  The chart shows the 
corresponding numerical values, and their p-values. 
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Amplitude (mmHg) 
Water Leakage vs Amplitude 
Source Sum Sq Probability 
Amplitude 0.29 1.64e-8 
Sample 0.84 4.42e-17 
Error 0.28 --- 
Total 1.40 --- 
The amplitudes of Figure18 were generated by keeping the average pressure the same, 
while increase oscillation amplitude by 30 for each data set.  The oscillations were kept at 
the same speed of 1 Hz.   When looking at the bar graph the average water leakage 
appears to gradually increase.  There does seem to appear to be a significant difference 
between the first and last data point.  The pie chart does show that the largest causal 
percentage for the variance in measurements was due to sample variance.  Variation 
attributed to amplitude has as much as an impact as natural variation in measurements.   
The table then shows that there is a statistical difference in amplitude with a p-value < 
0.01.    
 
Figure 19: Bar graph shows the water leakage as amplitude increases for both a 3 mm puncture hole, and a 4 
mm puncture hole.  The pie chart shows what percentage each variable contributes towards the standard 
deviation between data points.  The chart shows the corresponding numerical values, and their p-values. 
 
Figure 19 compares the water leakage as amplitude increases at different puncture sizes.   
Similar to Figure 16, there is a statistical difference between a 4 mm puncture and 3 mm 
puncture.  Despite the fact that the 3 mm puncture data set appears flat and almost non-
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existent, is the same data as shown in Figure 18.  When looking at the 4 mm puncture as 
amplitude increases, there is a small statistical difference between the lower two data 
sets, and the higher two data sets.  Similar to the 3 mm puncture, this correlation is only a 
slight increase.   
Figure 20 below shows the curve generated when using the falling ball viscometer to 
determine the viscosity of different PVP percent solutions.  As the percentage of PVP 
increases, an exponential increase in viscosity is shown.  The standard deviation for each 
point is shown, but are exceedingly small showing little variation.  The best fit line 
generates relationship between % PVP solutions and their viscosities, with an R
2
 as 
0.987. 
 
 
Figure 20: The graph shows viscosity of PVP and water solution as %PVP increases.  The equation generated 
from the curve us used in creating 400 ml solutions used in examining the coated stents. 
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Using the curve of Figure 13, three 400 ml solutions were made at 3.4%, 7.6%, and 
11.9% PVP.  These solutions were then used in testing three coated stents,electrospun for 
8 minutes, to determine how increase viscosity alters water leakage.  The pressure 
oscillated between 120 and 60 mmHg, and the flow speed of 90 ml/min.  Five 
consecutive measurements were taken with each stent, where each measurement lasted 
for 15 minutes. 
 
Figure 21: Graph shows the leakage measured with different viscous PVP solutions.  The horizontal error bars 
indicate the variance in viscosity for the 400 ml solutions measured using a falling ball viscometer.  Vertical 
error bars indicate standard deviation of leakage through stents.  The same 3 stents were used at each data 
point. 
 
The first data point used only water (1 cP) the medium in the TGT LumeGen bioreactor, 
while the other data points used a PVP and water solution of 3.4%, 7.6%, and 11.9% PVP 
with the goal of creating a 2, 4, and 8 cP viscous solution respectively.  When looking at 
the leakage as viscosity increases, the curve shows an exponentially downward sloping 
curve.  The curve generated the equation shown below with an R
2
 value of 0.974.   
y = 9.352e-0.26µ 
R² = 0.974 
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y= Solution leakage from coated stent 
µ= viscosity of solution  
 
 
Figure 22: Data plot shows that as pressure increases both PVP solution and water increase in water leakage.  
The PVP solution does not leak as much pure water.  Statistical significance becomes more apparent as pressure 
increases.  The same 3 stents were used when measuring water and 4 cP PVP solution. 
 
In Figure 22, it can be seen that as pressure increase both the water and PVP solution at 4 
centipoise increases as pressure increases.  The 4 centipoise solution was used as it 
closely resembles the viscosity of blood.  An initial condition with the pressure at 40 
mmHg was used in place of the 30 mmHg for the PVP solution because, due to the high 
viscosity of the solution and TGT LumeGen bioreactor limitations, the initial conditions 
for the average pressure could not be lowered to 30 mmHg while still maintaining a 
constant flow speed.  A statistical difference can be seen in stent leakage between the 4 
cP PVP solution and the 1 cP water medium at the higher pressures.  With lower 
pressures, there shows no statistical difference between the different viscous mediums. 
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 Figure 23: Data plot shows leakage in coated stents for both PVP solution and water as amplitude increases.  
The same 3 stents were used for measuring the leakage for the 4 cP solution and water medium.  The average 
pressure remained constant at 90 mmHg, while amplitude of the oscillations increased.  Flow speed remained 
constant at 90 ml/min. 
 
Figure 23 shows the leakage of the coated stent for a 4 cP PVP solution and water.  When 
looking at amplitude changes, both water and the PVP solution does not show no a 
positive or negative correlation as amplitude increases.  There is no statistical difference 
between the individual data sets.  However, when comparing the 4 cp PVP solution to the 
water solution, the water solutions shows a higher magnitude in leakage.  There is a clear 
statistical difference when comparing the 4 cP PVP solution and water at each of the 
individual amplitudes, where water leaks at least twice as fast through the coated stent.   
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Chapter 8: Discussion 
When looking at the time the vascular stents were electrospun for, they show no 
statistical difference in terms of water leakage.  This is different then what would be 
expected because as shown by weighing the stents before electrospinning and after, more 
material was placed on stents electrospun for 10 minutes as opposed to stents electrospun 
for a shorter period of time such as 6 minutes.  Also when looking at the SEM images 
from the vascular stents there seems to be a significant difference in the thickness of the 
coating of the vascular stents.  This difference in coating however does not seem to have 
any effect when placing the stents under biological conditions.  The reason for this may 
be that the stent porosity allows for the fluid to simply move through and around the 
cavities until it passes through the stent wall, and a thicker stent would only act in 
delaying the initial time taken in passing through the stent.   
When looking at the saturation in water of the stents over time, the stents when dry 
originally leak over a large range of values.  As Figure 13 shows, in the first 36 hours of 
saturation there is a steep decrease the average amount of leakage occurring.  After the 36 
hours, the amount of leakage levels off.  The same behavior can be seen for the standard 
deviation as well, where initially the standard deviation is very high, but after 36 hours 
this decreases to a steady consistent value.  This behavior is likely due to the nature of the 
polymer. When looking at the SEM images of the polyurethane fibers, they were shown 
to increase in diameter after being exposed to the physiological conditions in the TGT 
bioreactor.  While polyurethane is a hydrophobic polymer, it is not completely 
hydrophobic.  This would mean that some of the water would be absorbed by the fibers 
causing them to expand and swell.  This would lead to a more tightly sealed membrane.  
Along with a swelling of the fibers, the fibers had also deformed, shifting position and 
appearing to become more entangled within each other.  This caused the porosity of the 
membrane to decrease even farther reducing the leakage even more.   
The net effect would be a reduced level of leakage as well as a convergence in standard 
deviation.  Fibers that are initially electrospun onto the vascular stent are going to have an 
initial level of porosity, and leak a specific amount for the first measurement, but will 
leak a smaller amount by the second measurement as the fibers swell and shift position 
due to fluid flow and pulsatility.  Once the fibers have become fully saturated, and shifted 
themselves into a position that provides a less permeable membrane, the leakage and 
porosity will remain stable.   
What is also interesting is that the deformation that occurs after exposing the unused 
stents to pulsatile flow for 72 hours.  After the stents have shifted to their more stable 
positions the deformation that occurs from this shifting remains even after the stents have 
been dried.   They do not fully rebound back to the original level of leakage showing that 
some level of permanent deformation has occurred.  The full extent to the behavior of the 
stent is currently unknown.   For example, this may mean that future efforts in seeding 
cells onto the stents may need to include a precondition phase where the stents are 
exposed to pulsatile flow for 36 hours prior to seeding to ensure that the stent porosity 
remain consistent.   
As the average pressure increases in the TGT LumeGen bioreactor, the stents show a 
linear increase in the amount of leakage as well.  This is due to simple relationship that a 
high pressure system is going to force a larger amount of liquid through at a given period 
of time.  The higher the pressure the larger the amount of leakage will occur as the liquid 
was forced through the semi-permeable layer of the vascular stent.  This linear curve was 
consistently seen in the numerous graphs that looked at leakage as pressure increased. 
When looking Figures 14 and Figure 15 showing the Water leakage vs. Pressure for each  
of the electrospun times and the flow speeds  respectively, a consistency can be seen 
throughout each pressure changes where as pressure increases then the water leakage 
increases as well.  The significant differences for both figures were shown to be with the 
higher pressure of 90+/-30 mmHg and 120+/-30 mmHg being significantly different from 
each other and 60+/-30 mmHg.  At 30+/-30 mmHg and 60+/-30 mmHg no significant 
difference was seen.  The similarities between these figures, along with Figures 11 and 
12, indicate that pressure levels are significant factor in determining water leakage of the 
vascular stents.   
The leakage vs. viscosity demonstrated that viscosity has an exponential effect on the 
leakage of the vascular stents, where as the viscosity increases the water leakage 
decreases drastically initially and then begins to flatten out after 4 centipoise.  When 
comparing the higher viscosity solution of 4 centipoise to distilled and deionized water at 
1 centipoise, the higher viscosity showed the same trends, but shifting the curve to have 
less leakage through the vascular stents.  In the water leakage vs. pressure for Figure 22, 
the amount of leakage can be clearly distinguished between higher viscosities and lower 
viscosities.  However, when looking at lower pressures the discrepancies become less 
noticeable.  For Figure 23, similar to pressure, amplitudes for higher viscosities shows the 
same trend as the lower viscosity, but an order of magnitude lower.  This shows that the 
leakage for higher viscosities behave the same way, and hold the same patterns as lower 
viscosity substances, but their magnitudes are skewed to be lower with less impact 
between changes in either pressure or amplitude.   
The same idea can also be applied to puncture size, where decreasing the area that 
solution can travel between the inner wall and outer wall of the vascular stent, will 
decrease the magnitude of leakage, but hold the same basic pattern.  Figures 16 and 
19,show this comparing magnitudes and general trends in water leakage. 
It is unclear at this time if increasing the amplitude of pulsatility has any effect on the 
leakage of the vascular stents.  Figures 18 and 19 demonstrate a small positive correlation 
between water leakage and amplitude.  The increase that these graphs demonstrate is 
slight, where only the larger limits are statistically different then the smaller limits, but 
the anova tables do state that the p-value is less than 0.01.  At the same time Figure 19 
demonstrates no statistical difference between higher amplitudes and lower amplitudes.  
This was true for both a viscosity of 4 centipoise and 1 centipoise.   
It is possible that during the higher amplitudes the top peaks in pressure cause a small 
stretch of the area of the stent exposed to the puncture hole.  This small stretch would 
increase the porosity for a brief period of time, allowing for slightly more water or 
solution to pass through the stent wall.  Over time this small amount of liquid can build 
up allowing for a measurable difference to be calculated.  Whether or not there is a 
statistical difference due to increased amplitude, the net effect is negligible when 
compared other factors such as pressure increase, viscosity of the solution, puncture size, 
and saturation time.   
When comparing leakage of the electrospun polyurethane stents to other stents, the 
results of the leakage tests have shown similar results.  Vascular stents that were 12 mm 
in length and 3 mm in diameter where shown to have a water leakage of around 70 
ml/min when a thin covering (0.09 mg) of polyurethane material was electrospun on to 
the stent.  However, if a thicker covering (0.22 mg) were electrospun the water leakage 
would drop to be less then 1 ml/min (Kuraishi, Iwata et al. 2009).   The stents used in this 
thesis had between 1.9 mg and 3.6 mg of polyurethane electrospun on them depending on 
the thickness of the stent.  This means that the polyurethane stents used had at least 8 
times more material electrospun on each stent.  However, the stents used were 18 mm 
long, and had a diameter of 4 mm (JingjiaHan, Senel-Ayaza et al. 2015).  This gives a 
larger surface area.  Using the equation below a ratio between the two stents can be found 
to directly compare how much material was deposited on each stent. 
       
A = surface area 
r = stent radius  
L= stent length 
 
The stents used showed a surface area of 226 mm
2
, while the other stents were 113 mm
2
.  
This means that these polyurethane stents had a surface area half the size of the 
polyurethane stents used in this thesis.  With the surface area half the size of the stents 
used, and the amount of polyurethane material being less than half the material deposited 
than the stents used, shows that the polyurethane stents with 0.22 mg of polyurethane had 
less material electrospun on them per surface area than the stents used. 
The method for measuring the water leakage was done similar to the method done in this 
thesis, where a 3 mm hole was cut into a silicon tubing.  The apparatus used to create 
flow and pressure was similar to the design described in 5.2 Preliminary Flow Design, 
with pipe height of 60 cm, creating a constant pressure of 45 mmHg.  This is below 
physiological diastolic pressures, and as the results of this thesis has shown, that as the 
pressure levels increase, the water leakage will increase as well.  The other limitations of 
the design have already been described in 5.2 Preliminary Flow Design. 
 Despite the difference in designs used, the results in water leakage are still consistent in 
that the vascular stents with a surface area of 113 mm
2
 that have at least 0.22 mg of 
polyurethane material electrospun onto them show a water leakage of less than 1 ml/min.  
Table 4 shows a direct comparison the water leakage of the different polyurethane stents 
used.   
A chitosan-polyethalene glycol covered stent showed that membrane leakage was 1 
mL/cm2 min−1 at 120 mmHg (Thierry, Merhi et al. 2005). From the results in Figure 14 
above, the polyurethane stents were shown to have an average leakage of 0.8 ml.   Each 
of the leak test for the polyurethane covered stents lasted for 15 minutes, and the area 
cut for the water to permeate through was a 3 mm hole giving a permeable area of 0.07 
cm2.  This means that the water leakage was 0.8 ml/0.07cm2 15 min-1 (0.76 ml/cm2 min-
1)  Table 4 shows a direct comparison between the water leakage of different types of 
stents.   
The chitosan-polyethalene glycol cover was made by using a gel casting system where 
the chitosan-polyethalene glycol gel was poured over the stent as it rotated along a 
mantrel.  The constant viscosity and the constant speed of the mandrel allowed for a 
uniform distribution of the cover.  It was then dried (Thierry, Merhi et al. 2005) 
The method used for measuring the water leakage each of these covered membranes is 
another water column device.  The details for design for the water column can be found 
(Phaneuf, Dempsey et al. 2001) where the basic design is a water source is held 165 cm 
above the stent to provide a pressure of 120 mmHg.  Fittings hold the tested segment in 
place, and keep the segment stretched.   Any water passing through the membrane is 
collected in a graduated cylinder and measured.    
Along with vascular stents, vascular grafts have used the same methods for testing water 
periability of the membrane, and are used as an alternative solution to vascular stents in 
preventing coronary heart disease.  Polyether-based urethane with carboxylic acid groups 
(PEU-D) grafts have shown a water permeation of 1.1 +/- 1.9 ml/cm
2
 min
-1
.  They were 
made by incorporating the polyether-based urethane was spread throughout the interior of 
graft with a perfusion system.  Details can be found in (Phaneuf, Dempsey et al. 2001).  
Crimped knitted Dracon grafts that have been crosslinked with collegen has a water 
permeation of 9.8 +/- 10 ml/cm
2
 min
-1
.   These are currently clinically available grafts 
used as a gold standard for vascular grafts.  Crimped knitted Dacron vascular grafts 
segments without any extra crosslinking were tested in the water column system.  Since, 
they did not have any coating and had a water permeation of 2820 +/ -344 ml/cm
2
 min
-1
 
(Phaneuf, Dempsey et al. 2001). Table 4 shows a direct comparison between the vascular 
grafts and the vascular stents. 
 
Membrane 
Material 
Pressure Water Leakage 
Polyurethane 30  / 120 
mmHg 
0.47 / 0.76         
ml/cm2 min−1 
Polyurethane 
(Thin) 
45 mmHg 
 1000 ml/cm2 
min−1 
Polyurethane 
(Thick) 
45 mmHg  > 1 ml/cm2 min−1 
chitosan-
polyethalene 
glycol 
120 mmHg 1 ml/cm2 min−1 
PEU-D graft 120 mmHg 1.1 ml/cm
2 min-1 
Crimped 
knitted Dracon 
(with collegen) 
120 mmHg 9.8 ml/cm2 min-1 
Crimped 
knitted Dracon 
(without 
collegen) 
120 mmHg 
2820 ml/cm2 min-
1 
Table 4: Directly compares the water leakage of different vascular stents and grafts.   The bold 
polyurethane shows the water leakage for the stents used in this thesis. 
 
When comparing the water leakage of the polyurethane covered stents used, and the 
rest of the field show that they have less or equal water leakage.  The major difference 
seem to be that the method currently utilized in determining the water leakage is 
through the use of a water column design.  This is a major problem because a water 
column design are not able to fully determine the properties of the vascular stent.  A 
water column design is capable of only determining the water leakage at a single 
pressure.  As Figure 14 above has shown, the amount of fluid leakage changes as the 
pressure increases or decreases.  Also as Figure 13 and Image 1 has shown, the 
properties of the vascular stent may change with time depending on the material used 
as the membrane.  These factors are not incorporated or addressed when quantifying 
the water leakage of the vascular stents when using water columns are not capable of 
measuring the water leakage over a range of pressures. 
Further efforts should be made to improve the methods utilized in the water of the 
vascular stent, so that they are more reflective of the physiological and 
pathophysiological conditions.  Schurink et al. has done this by constructing an in vitro 
model of aneurysm with the use of a pulsatile pump, reservoirs, flow meters, pressure 
transducers, and an artificial aneurysm.  The details of the model can be found (Schurink, 
Aarts et al. 1998), but the model allows for a control in pressure, flow rate, and 
incorporates pulsatility as well as the wall thinning typically seen in aneurysms, as well 
as a location where the anseurysm bursts.   With this model, they are capable of 
understand endoleakage in a controlled and repeatable method that is very difficult to 
achieve with in vivo methods, while still being able to mimick physiological and 
pathophysiological conditions.  Pulsatile flow systems should be used as the new gold 
standard when looking at vascular leakage instead of water columns because they give a 
more complete understanding of the vascular stents behavior when exposed to 
physiological and pathophyiological conditions.    
 Chapter 9: Limitations 
 9.1: Vascular Substitute 
The modified TGT LumeGen bioreactor allows for the polyurethane electrospun coated 
vascular stents’ performance to be evaluated under near biological conditions.  However, 
the system is not a perfect replication of the body.  One of the shortcomings from the 
design is that the Tygon® tubing used surrounding the deployed stent is not an accurate 
representation of a blood vessel.  The walls of the tubing is 1.5 mm thick, minimum size 
available, giving the substituted vessel a much more rigid and stiff composition.   
Natural blood vessels are elastic allowing for the vessel wall to stretch as the pressure 
increases and decreases during oscillations.  When the wall of the blood vessel weakens, 
the vessel to swell and expand, an aneurysm.  Once the vessel wall has sufficiently 
weakened, the aneurysm will burst causing hemorrhaging to occur.  The Tygon® tubing 
does not mimic this function.  The thickness of the walls and the rigidity of the material 
prevent the tubing from contracting or expanding during pulsations.  The weakened 
portion of the tubing surrounding the punctured hole does not expand either when placed 
under biological flow conditions.  As such, any differences this may cause in 
performance for the vascular stents was not accounted for.   
 
 
 
 9.2: Surrounding Pressure 
Similar to how the Tygon® tubing does not mimic the properties of a natural blood 
vessel, the leak chamber does not mimic tissue found surrounding the aneurysm.  When 
an aneurysm bursts, the blood hemorrhages into the surrounding tissue causing internal 
bleeding.  The surrounding tissue will apply some level of force and pressure, amount 
depending on what tissue is surrounding and where the aneurysm occurs, back on the 
puncture area.  This will reduce the change in pressure from inside the blood vessel to 
outside the blood vessel, and reduce the rate at which blood will leak out of the puncture 
wound.   
The leak chamber does not provide any resistive force.  The change in pressure from 
inside the coated stent wall and outside the coated stent wall goes from the initial 
conditions placed into the system to atmospheric pressure.  While, this was done to 
accurately collect and measure the leakage rate, it still provides a systematic error in how 
much solution leaks through the stent covered puncture hole.   
9.3: Biological Interaction 
Another limitation in the design was there was no biological active component when 
measuring the leakage rate of the stents.  The PVP solution, substituted because of the 
time requirement needed to obtain proper IRB certificationfor blood, was able to mimic 
the viscosity of whole blood, but was not able to mimic the protein or cellular interaction 
that would occur in blood was used.   In the body, proteins and cells provide a dynamic 
and constantly active environment.  If an aneurysm were to occur in the body, many 
protein and cellular interactions would occur such as signaling factors to alert 
surrounding cells and platelet formation to allow a clot to form.   
When evaluating the performance of the vascular stents, no biological component was 
introduced because of both time and simplicity in evaluating factors.  The lack of a 
biologically active environment may cause a significant difference in the amount of 
leakage occurring in the vascular stents, specifically as time increased.   
 9.4: Sample Size 
Due to the limited amount of fully coated stents available, the sample size for each of 
factors being tested remained at three.  Five tests were done on each sample to more 
accurately reflect the consistency in each sample, but this still allows for a systematic 
error in sample value.  Two and Three variable anova tests were also used to better 
compensate for the limited sample size, and more accurately display the data.  Still, when 
not enough stents were available, some vascular stents needed to be reused across 
multiple testing variables.   
Chapter 10: Future Work 
 10.1: Cellular Seeding 
Now that analyzing the behavior of the vascular stents without any cellular activity has 
been characterized, it will be important in the future to see how these results compare to 
stents that have been seeded with endothelial cells.  The function of any coated vascular 
stent is to eventually be placed into a blood vessel to prevent atherosclerosis and 
aneurysms from bursting.  Endothelial cells line the lumen of the blood vessel, and will 
contact the vascular stent when deployed.  It will be important to know how these 
endothelial cells interact with the polyurethane stents. Many of the important aspects of 
this will include understanding cell viability, cellular proliferation, and cellular 
differentiation when using endothelial progenitor cells.   
Along with understanding how the how the cells will interact with the coated stent, it is 
important to understand how the coated stents will interact with the cells.  This will 
include looking at performance leakage at different stages of cellular proliferation 
compared to non-cellularized stents.   Looking at any degradation the polyurethane 
coating occurs when seeded with cells for a long period of time, and seeing if any pre-
conditioning stages need to made before seeding the cells.   
10.2: Drug Loading 
One of the main functions of coated stents is the ability to incorporate drug loaded 
nanoparticles into the structure.  These drugs can be used to solve many problems in the 
blood vessels such as restenosis.  By looking at the electrospinning process used to 
manufacture these coated vascular stents, either nanoparticles or microbeads may be able 
to incorporated into the electrospun structure.  Once the drug has been loaded onto the 
stent, the bioreactor will be able to compare the leakage performance of the drug-loaded 
stent vs the non-drug loaded stent, as well as looking at the local diffusion of the drug 
over time. 
10.3: Animal Testing 
Even though the TGT LumeGen bioreactor has the ability to mimic many of the 
mechanical forces present in the cardiovascular system of a living organism, it still 
cannot mimic many of the biological effects seen in a living organism.  Animal testing 
will still need to be done to ensure that the product has the ability to quantifiably prevent 
restenosis from occurring, stop an aneurysm from bursting, or plugging any small 
perforations from hemorrhaging blood.  Along with simply testing to see if the coated 
stents function in an animal, tests will need to be done to see if any immune responses 
from the vascular stents would compromise the animal’s health.  These are just some of 
the many tests that will need to be done ensure that the electrospun polyurethane coated 
vascular stents are ready to actively and safely placed in humans.   
 
  
Chapter 11: Conclusion 
Due to the low sample size, it can be hard to predict with certainty if the results gathered 
are reflective of the true behavior of electrospun polyurethane covered-stents when 
placed under extreme physiological conditions.  However, if these preliminary results are 
reflective of a continued trend then it can be stated that the electrospun polyurethane 
covered-stents are capable of with withstanding extreme physiological conditions without 
rupture.  Many of the isolated factors showed no impact in water leakage such as flow 
speed, pulsatility vs. continuous flow, and electrospun time.  The electrospun time 
particularly shows that the thickness of polyurethane cover does not have a net effect on 
its ability to reduce water leakage.  Other isolated variables behaved as expected, such as 
with pressure and porosity increasing the water leakage would increase, and as viscosity 
increased measured leakage decreased.   
With the prolonged exposure to pulsatile conditions altering the leakage of the 
polyurethane covered-stent, it is possible a preconditioning phase would need to be 
introduced to preparing the stents to allow for a more consistent behavior.  Additional 
testing will need to be done to see if this will have any effect on endothelial proliferation. 
These results support the research of that polyurethane covered-stents are capable of 
withstanding physiological conditions, and are a viable method for reducing the 
prevalence of in-stent restenosis.    
Chapter 12: Index 
Figures 24, 25, and 26 will show the water leakage as pressure increases with the 6 
minute, the 8 minute, and the 10 minute electrospun stents respectively.  Each one the 
flow speed remained constant at 90 ml/min, and each data point consisted of three 
samples, with each sample measured five times consecutively for 15 minutes per 
measurement.   The average pressure was increased by 30 mmHg for each data point, but 
the oscillation amplitude remained +/- 30, where each oscillation was at a frequency of 1 
Hz.  Each of the graphs shows the similar results where as pressure increases the water 
leakage increases.  The data from all three figures was used to create Figure 14. 
 
 
Figure 24: Line graph shows the water leakage as pressure increases for 6 minute electrospun stents.  The pie 
chart uses a 2 variable anova to show how much each variable is responsible for statistical difference.  Table 
shows the corresponding numerical values. 
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Sample 1.12 3.9e-10 
Error 0.53 --- 
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Figure 25: Line graph shows water leakage as pressure increase for 8 minute electrospun stents.  The pie chart 
shows what percentage each variable contributes towards the standard deviation.  The table shows the 
corresponding numerical values and p-values of each variable. 
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Figure 26: Line graph shows the water leakage as pressure increases for 10 minute electrospun stents.  The pie 
chart shows the percentage each variable contributes towards the standard deviation.  The table shows the 
corresponding numerical values and the p-value. 
 
Figures 27, 28, and 29 will show the water leakage as pressure increases with a flow 
speed of 45 ml/min, 90 ml/min, and 180 ml/min.Stents were electrospun for 8 minutes 
each with each data point consisted of three samples. Each sample was measured five 
times consecutively for 15 minutes per measurement.   The average pressure was 
increased by 30 mmHg for each data point, but the oscillation amplitude remained +/- 30, 
where each oscillation was at a frequency of 1 Hz.  Each of the graphs shows the similar 
0.00
0.50
1.00
1.50
2.00
30 +/- 30 60 +/- 30 90 +/- 30 120 +/- 30
W
at
e
r 
Le
ak
ag
e 
(m
l)
 
Pressure (mmHg) 
Water Leakage vs Pressure (10 minutes electrospun) 
Source Sum Sq Probability 
Pressure 3.48 1.35e-8 
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results where as pressure increases the water leakage increases.  The data from all three 
figures was used to create Figure 16. 
 
 
Figure 27: The line graph shows the water leakage as pressure increases with a flow rate of 45 ml/min.  The pie 
chart shows how each variable contributes towards the standard deviation.  The table gives a corresponding 
numerical values and p-values for each variable. 
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Figure 28: The line graph shows the water leakage as pressure increases with a flow rate of 90 ml/min.  The pie 
chart shows how each variable contributes towards the standard deviation.  The table gives a corresponding 
numerical values and p-values for each variable. 
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Figure 29: The line graph shows the water leakage vs pressure for a flow speed of 180 ml/min.  The pie chart 
indicates what percentage each variable contributes towards the standard deviation.  The table gives the 
corresponding numerical values and the p-value determining any statistical difference. 
Figures 30, 31, and 32 will show the water leakage when comparing pulsatile flow vs. 
continuous flow ata flow speed of 45 ml/min, 90 ml/min, and 180 
ml/minrespectively.Stents were electrospun for 8 minutes each with each data point 
consisted of three samples. Each sample was measured five times consecutively for 15 
minutes per measurement.   The continuous flow showed an average pressure of 90 
mmHg with no oscillation in the flow.  The pulsatile flow had an average pressure of 90 
mmHg with an oscillation of 30 mmHg, where each oscillation was at a frequency of 1 
Hz.  Each of the graphs shows the similar results showing no significant difference 
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between continuous flow and pulsatile flow.  The data from all three figures was used to 
create Figure 17. 
 
 
 
Figure 30: Indicates pulsatile flow vs. continuous flow at a flow speed of 45 ml/min.  The pie chart shows what 
percentage each variable contributes towards the standard deviation.  The chart gives the corresponding 
numerical values and p-values. 
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Figure 31: Indicates pulsatile flow vs. continuous flow at a flow speed of 90 ml/min.  The pie chart shows what 
percentage each variable contributes towards the standard deviation.  The chart gives the corresponding 
numerical values and p-values. 
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Figure 32: Indicates pulsatile flow vs. continuous flow at a flow speed of 180 ml/min.  The pie chart shows what 
percentage each variable contributes towards the standard deviation.  The chart gives the corresponding 
numerical values and p-values. 
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